Board of Directors

Richard Samuel, Chief Investment Officer

Mr. Samuel is the Chief Investment Officer of the Lotus Energy Group, a global energy infrastructure provider with a focus on the deployment of distributed generation and micro-grid projects employing gas turbine, solar and wind power generating technologies.

He has over 25 years in the global financial buyout market and has deep experience in raising debt and equity financing for privately held companies. Previous roles include senior executive positions at leading European financial institutions, including Alcentra limited (investment subsidiary of Bank of New York Mellon), Intermediate Capital Group and Deutsche Bank/Morgan Grenfell.

Mr Samuel holds several Non-Executive board positions which include: Simplisim Group Limited, PR Facilities Management Limited and SGC Wine Limited; was a graduate of the University of Toronto (B. Comm), and is a Chartered Financial Analyst.

Simon Retter, Chairman

Founder of Adalan Ventures Plc, Simon James Retter presently holds the position of Chairman of FPP. He has also been Finance Director & Director at Vertu Capital Ltd. which is presently listed on the London Stock Exchange, Finance Director of SulNox Group plc and currently holds the position of Non-Executive Director at ElixIrr International plc . Mr. Retter has extensive listed company experience and is also Member of Institute of Chartered Accountants in England & Wales.

Simon James Retter received an undergraduate degree from the University of Bristol.

Mahesh Pulandaran

Mahesh Pulandaran joined the board of Fragrant Prosperity Holdings with effect from October 31; 2018. In his career, Mr. Pulandran advised various blue chip companies including Microsoft Corp and Caterpillar Inc. Fragrant was formed to undertake an acquisition of a target company or business in in Europe or Asia.

Dr. Daniel Reshef

Dr. Daniel Reshef is a dual Israeli and USA Citizen, currently living in the USA, with strong ties to Israel, Israel medical research centers and a vast array of relationships in the global pharmaceutical sector.

Dr Reshef’s extensive career with over twenty five years in drug development encompasses many facets of the Pharmaceutical sector, gained through senior management positions at leading companies such as Hoffman La Roche, Genentech, Bristol Myers Squibb, and in his current capacity as the Therapeutic Area Global Head for a major global Pharmaceutical Company. His scientific experience includes skills in regulatory, medical affairs, drug safety operations and clinical trials epidemiology with leadership experience in early drug development from phase 1 to phase IV, and in multiple therapeutic areas.

Dr. Reshef is a board-certified physician, graduate of the Hebrew University and Hadassah Medical School in Jerusalem, and has earned his MPH and PhD in Epidemiology from Johns Hopkins University.